Journal Article Epublish
PubMed: 35214660 DOI: 10.3390/vaccines10020201
Is the BCG Vaccine an Answer to Future Pandemic Preparedness?
Vaccines (Basel) 10(2)
Authors: Nadia H Khan, Nadine G Rouphael, Lindsey R Baden, Daniel S Graciaa
Affiliations
- College of Agriculture and Life Sciences, Cornell University, Ithaca, NY 14850, USA.
- Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
- Division of Infectious Diseases, Brigham and Women's Hospital (BWH), Harvard Medical School, Boston, MA 02115, USA.
Abstract
While the development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines was rapid, time to development and implementation challenges remain that may impact the response to future pandemics. Trained immunity via bacille Calmette-Guerin (BCG) vaccination (an antigen agnostic strategy) offers a potential intervention against future novel pathogens via an existing, safe, and widely distributed vaccine to protect vulnerable populations and preserve health system capacity while targeted vaccines are developed and implemented.
MeSH
Bcg Vaccine, Sars-Cov-2, Vaccines, Pandemics